These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Kröger N; Alchalby H; Klyuchnikov E; Badbaran A; Hildebrandt Y; Ayuk F; Bacher U; Bock O; Kvasnicka M; Fehse B; Zander A Blood; 2009 Feb; 113(8):1866-8. PubMed ID: 19228938 [No Abstract] [Full Text] [Related]
7. Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation. Lee JM; Ahn A; Min EJ; Lee SE; Kim M; Kim Y Blood Cancer J; 2023 Jun; 13(1):97. PubMed ID: 37365186 [No Abstract] [Full Text] [Related]
8. Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation. Steckel NK; Koldehoff M; Ditschkowski M; Beelen DW; Elmaagacli AH Transplantation; 2007 Jun; 83(11):1518-20. PubMed ID: 17565328 [TBL] [Abstract][Full Text] [Related]
9. Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation. Benjamini O; Koren-Michowitz M; Amariglio N; Kroger N; Nagler A; Shimoni A Leukemia; 2008 Oct; 22(10):1961-3. PubMed ID: 18685610 [No Abstract] [Full Text] [Related]
10. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood. Poodt J; Fijnheer R; Walsh IB; Hermans MH Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961 [TBL] [Abstract][Full Text] [Related]
11. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789 [TBL] [Abstract][Full Text] [Related]
12. Eradication of JAK2 V617F mutation after allogeneic transplantation in a patient with myelofibrosis with myeloid metaplasia. Fiorini A; Reddiconto G; Farina G; Marietti S; Palladino M; Chiusolo P; Leone G; Sica S Leukemia; 2006 Dec; 20(12):2198-9. PubMed ID: 17039230 [No Abstract] [Full Text] [Related]
13. Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT. Alchalby H; Badbaran A; Bock O; Fehse B; Bacher U; Zander AR; Kröger N Bone Marrow Transplant; 2010 Sep; 45(9):1404-7. PubMed ID: 20062088 [TBL] [Abstract][Full Text] [Related]
14. No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis. Ditschkowski M; Elmaagacli AH; Trenschel R; Steckel NK; Koldehoff M; Beelen DW Biol Blood Marrow Transplant; 2006 Dec; 12(12):1350-1. PubMed ID: 17162218 [No Abstract] [Full Text] [Related]
15. Evaluation of a JAK2 V617F quantitative PCR to monitor residual disease post-allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms. Haslam K; Molloy KM; Conneally E; Langabeer SE Clin Chem Lab Med; 2014 Mar; 52(3):e29-31. PubMed ID: 24423581 [No Abstract] [Full Text] [Related]
16. Allele-specific wild-type blocker quantitative PCR for highly sensitive detection of rare JAK2 p.V617F point mutation in primary myelofibrosis as an appropriate tool for the monitoring of molecular remission following therapy. Siebolts U; Lange T; Niederwieser D; Wickenhauser C J Clin Pathol; 2010 Apr; 63(4):370-2. PubMed ID: 20354212 [TBL] [Abstract][Full Text] [Related]
17. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR. Waterhouse M; Follo M; Pfeifer D; von Bubnoff N; Duyster J; Bertz H; Finke J Ann Hematol; 2016 Apr; 95(5):739-44. PubMed ID: 26931113 [TBL] [Abstract][Full Text] [Related]
18. Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era? Lestang E; Peterlin P; Le Bris Y; Dubruille V; Delaunay J; Godon C; Theisen O; Blin N; Mahe B; Gastinne T; Garnier A; Touzeau C; Voldoire M; Bene MC; Le Gouill S; Milpied N; Mohty M; Moreau P; Guillaume T; Chevallier P Eur J Haematol; 2017 Jul; 99(1):60-69. PubMed ID: 28370306 [TBL] [Abstract][Full Text] [Related]
19. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Barosi G; Bergamaschi G; Marchetti M; Vannucchi AM; Guglielmelli P; Antonioli E; Massa M; Rosti V; Campanelli R; Villani L; Viarengo G; Gattoni E; Gerli G; Specchia G; Tinelli C; Rambaldi A; Barbui T; Blood; 2007 Dec; 110(12):4030-6. PubMed ID: 17712047 [TBL] [Abstract][Full Text] [Related]
20. Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma. Kröger N; Zagrivnaja M; Schwartz S; Badbaran A; Zabelina T; Lioznov M; Ayuk F; Zander A; Fehse B Exp Hematol; 2006 May; 34(5):688-94. PubMed ID: 16647575 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]